Karolina Mizeracka

so many answers to questions we were pondering long ago 🥹

so cool you can go to this!!! good to hear LHS continues to dominate

Boston Has Worms (The Good Kind) Inside the world of C. elegans worms and the scientists who know them best.

Delighted to share this timely article in Boston magazine on our local C. elegans community and the effects of NIH freezes.

"There might be no group more enthusiastic, self-aware, or life-affirming than the worm people."

www.bostonmagazine.com/news/c-elega...

Induced proximity pushes beyond protein degraders, as first RIPTAC moves into the clinic Halda Therapeutics has started a clinical trial of its first-in-modality RIPTAC drug HLD-0915 in prostate cancer, to see if bifunctional drugs can provide tissue-specific activity.

Congratulations to Kat Kayser-Bricker and the Halda team on leading the efforts to advance RIPTACs to clinic! Also commentary from @danetteldaniels.bsky.social on what this means for the field as well as work being done at Foghorn in this space.
www.nature.com/articles/d41...

Excited about programming biology via induced proximity? Then mark June 2026 in your calendar and consider participating in the GRC Conference on Induced Proximity Modalities and Therapeutics that I am co-organizing with @danetteldaniels.bsky.social
tinyurl.com/brtuffam

Implications of frequent hitter E3 ligases in targeted protein degradation screens - Nature Chemical Biology This Perspective discusses recent strategies to expand the scope of targeted protein degradation (TPD) and the implications of unexpected convergence of diverse screening efforts on a small subset of ...

Thoughts on why DCAF11, DCAF16 and FBXO22 could be the next workhorse E3 ligases in TPD
doi.org/10.1038/s415...

So happy to see the growth of our initiative to now offer conference scholarships! Apply below for consideration.
Happy 2025 ☺️☀️☺️